VICTOR CHEANG: Open Payments
NPI 1528240926 · LOS ANGELES, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,762 in 76 payments from 9 companies in 2025. Trend: 2023 $3,251 · 2024 $3,157 · 2025 $3,762
Food & beverage: $3,762
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 15 | $732 |
| Janssen Pharmaceuticals, Inc | 9 | $628 |
| Alkermes, Inc. | 15 | $585 |
| Teva Pharmaceuticals USA, Inc. | 7 | $499 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 11 | $453 |
| Otsuka America Pharmaceutical, Inc. | 14 | $441 |
| Neurocrine BioSciences, Inc. | 2 | $248 |
| Vanda Pharmaceuticals Inc. | 2 | $158 |
| ABBVIE INC. | 1 | $17 |
Products named: COBENFY, INVEGA SUSTENNA, ARISTADA, CAPLYTA, UZEDY, INGREZZA, AUSTEDO XR, REXULTI.
Industry payments across CA — which companies pay providers there.
